Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
107.95
-2.74 (-2.48%)
Aug 6, 2026, 4:00 PM EDT - Market closed
Corcept Therapeutics Employees
Corcept Therapeutics had 730 employees as of December 31, 2025. The number of employees increased by 230 or 46.00% compared to the previous year.
Employees
730
Change (1Y)
230
Growth (1Y)
46.00%
Revenue / Employee
$1,138,100
Profits / Employee
$74,342
Market Cap
11.67B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 730 | 230 | 46.00% | 730 | 0 |
| Dec 31, 2024 | 500 | 148 | 42.05% | 500 | 0 |
| Dec 31, 2023 | 352 | 53 | 17.73% | 352 | 0 |
| Dec 31, 2022 | 299 | 61 | 25.63% | 299 | 0 |
| Dec 31, 2021 | 238 | 2 | 0.85% | 238 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,100 |
| Axsome Therapeutics | 1,220 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 673 |
| Halozyme Therapeutics | 423 |
CORT News
- 2 days ago - Raised Guidance Lifts Corcept to 52-Week High - FXEmpire
- 7 days ago - Corcept Therapeutics price target raised to $161 from $150 at Canaccord - TheFly
- 7 days ago - Corcept Therapeutics price target raised to $165 from $88 at Piper Sandler - TheFly
- 8 days ago - Corcept Therapeutics price target raised to $165 from $95 at H.C. Wainwright - TheFly
- 8 days ago - Corcept Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 8 days ago - Corcept Therapeutics Earnings release: Q2 2026 - Filings
- 8 days ago - Corcept Therapeutics Quarterly report: Q2 2026 - Filings
- 8 days ago - Corcept Therapeutics reports Q2 EPS 36c, consensus 5c - TheFly